These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 27173230)

  • 1. Comparison of the antiplatelet effect of clopidogrel benzene sulfonate and clopidogrel hydrogen sulfate in stable coronary heart disease.
    Wang SH; Li X; Hou FL; Tian YJ; Liu YH; Zheng SL
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.
    Hamilos M; Saloustros I; Skalidis E; Igoumenidis N; Kambouris M; Chlouverakis G; Vougia D; Loggakis I; Vardas PE; Kochiadakis G
    J Thromb Thrombolysis; 2015 Oct; 40(3):288-93. PubMed ID: 25662861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
    Arya V; Mahajan P; Saraf A; Mohanty A; Sawhney JP; Bhargava M
    Int J Lab Hematol; 2015 Dec; 37(6):809-18. PubMed ID: 26264906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
    Hokimoto S; Chitose T; Mizobe M; Akasaka T; Arima Y; Kaikita K; Iwashita S; Morita K; Miyazaki H; Oniki K; Matsui K; Nakagawa K; Ogawa H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: a retrospective study.
    Borsiczky B; Sarszegi Z; Konyi A; Szabados S; Gaszner B
    Thromb Res; 2012 Jun; 129(6):700-3. PubMed ID: 21924759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment.
    Siasos G; Zaromitidou M; Oikonomou E; Mourouzis K; Tsalamandris S; Kioufis S; Kokkou E; Vavuranakis M; Zografos T; Antonopoulos A; Dimitropoulos S; Stefanadis C; Papavassiliou AG; Tousoulis D
    Curr Pharm Des; 2015; 21(34):5041-6. PubMed ID: 26311225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation.
    Lim S; Kim PJ; Baek C; Kim TH; Koh YS; Park HJ; Kim HY; Chang K; Chung WS; Seung KB
    Clin Drug Investig; 2015 Dec; 35(12):833-42. PubMed ID: 26507618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study.
    Neubauer H; Krüger JC; Lask S; Endres HG; Pepinghege F; Engelhardt A; Bulut D; Mügge A
    Clin Res Cardiol; 2009 Sep; 98(9):533-40. PubMed ID: 19504141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy.
    Arima Y; Kaikita K; Ishii M; Ito M; Sueta D; Oimatsu Y; Sakamoto K; Tsujita K; Kojima S; Nakagawa K; Hokimoto S; Ogawa H
    J Thromb Haemost; 2016 Apr; 14(4):850-9. PubMed ID: 26773298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy].
    Muslimova EF; Afanasiev SA; Rebrova TY; Sergienko TN; Repin AN
    Ter Arkh; 2017; 89(5):74-78. PubMed ID: 28631703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
    Carreras ET; Hochholzer W; Frelinger AL; Nordio F; O'Donoghue ML; Wiviott SD; Angiolillo DJ; Michelson AD; Sabatine MS; Mega JL
    Thromb Haemost; 2016 Jul; 116(1):69-77. PubMed ID: 27009617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
    Gajos G; Zalewski J; Nessler J; Zmudka K; Undas A; Piwowarska W
    Kardiol Pol; 2012; 70(5):439-45. PubMed ID: 22623230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate.
    Tsoumani ME; Kalantzi KI; Dimitriou AA; Ntalas IV; Goudevenos IA; Tselepis AD
    Angiology; 2012 Oct; 63(7):547-51. PubMed ID: 22144668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.